# Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

> **NCT04363697** · PHASE4 · COMPLETED · sponsor: **The TIMI Study Group** · enrollment: 2401 (actual)

## Conditions studied

- Acute Heart Failure
- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04363697
- **Lead sponsor:** The TIMI Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-24
- **Primary completion:** 2025-06-02
- **Final completion:** 2025-06-02
- **Target enrollment:** 2401 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04363697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04363697, "Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04363697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*